AI assistant
Akari Therapeutics Plc — Director's Dealing 2015
Jan 2, 2015
34762_dirs_2015-01-02_0bc3f46f-e6ce-4eaa-9ff0-cd428e772aee.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3 — Initial Statement of Beneficial Ownership
Issuer: Celsus Therapeutics Plc. (CLTX)
CIK: 0001541157
Period of Report: 2015-01-01
Reporting Person: LAU JOHNSON YIU NAM (Director)
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Options to Purchase Ordinary Shares | $ | 2017-08-28 | Ordinary Shares (68250) | Direct | |
| Options to Purchase Ordinary Shares | $1.56 | 2022-03-19 | Ordinary Shares (25000) | Direct | |
| Options to Purchase Ordinary Shares | $1.56 | 2022-06-20 | Ordinary Shares (30000) | Direct | |
| Options to Purchase Ordinary Shares | $2.00 | 2023-04-29 | Ordinary Shares (70000) | Direct | |
| Options to Purchase Ordinary Shares | $0.75 | 2024-02-05 | Ordinary Shares (25000) | Direct | |
| Options to Purchase Ordinary Shares | $0.60 | 2024-07-22 | Ordinary Shares (45000) | Direct |
Footnotes
F1: 50% of shares underlying the options vested on 8/28/2008 and the remaining 50% of shares underlying the options vested on 8/28/2009.
F2: 100% of the shares underlying the options vested on 3/19/2013.
F3: 100% of the shares underlying the options vested on 6/20/2012.
F4: 1/3 of the shares underlying the options vest annually, beginning on 4/26/2014.
F5: 100% of the shares underlying the options vested on 5/31/2014.
F6: 100% of the shares underlying the options will vest on 6/1/2015.
F7: The exercise price for these options to purchase ordinary shares is 0.80 pound sterling.